Gilead Sciences Inc. (GILD)
Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Leerink Partners Global Healthcare Conference Call March 11, 2025 10:40 AM ET Company Participants Cindy Perettie - Executive Vice President and Global Head, Kite Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch I think we'll get started. Hi, everyone.
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Buy Gilead Sciences (GILD) Stock at 52-Week Highs?
Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks.
Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
Pharmaceutical Stocks Hit New Highs Amid Market Volatility
During this time of heightened market volatility, it pays to be invested in the right places.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the preceding trading day.
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.
Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Gilead Sciences Remains A Buy After A 40% Rally
Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by rising demand for Biktarvy, Descovy, and Sunlenca. So, sales of Biktarvy, the flagship of Gilead's HIV franchise, amounted to $3.77 billion, an increase of 21.4% year-on-year.
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Sciences Inc. NASDAQ: GILD stock surged to a new 52-week high at $106.69 recently on its fourth quarter of 2024 earnings release. After being asleep for so many years, the stock has finally found interest again, hitting price levels not seen in a decade.
